Total Payments
$1,638
2024 Payments
$969.09
Companies
22
Transactions
137
Medicare Patients
2,548
Medicare Billing
$154,144
Payment Breakdown by Category
Food & Beverage$1,625 (99.2%)
Other$13.58 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,625 | 136 | 99.2% |
| Debt forgiveness | $13.58 | 1 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $504.29 | 74 | $0 (2024) |
| Novo Nordisk Inc | $152.69 | 9 | $0 (2024) |
| GlaxoSmithKline, LLC. | $116.46 | 6 | $0 (2024) |
| Lilly USA, LLC | $87.67 | 6 | $0 (2024) |
| Exact Sciences Corporation | $86.16 | 5 | $0 (2024) |
| Axsome Therapeutics, Inc. | $82.13 | 5 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $73.72 | 4 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $72.68 | 3 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $70.28 | 4 | $0 (2024) |
| Medtronic, Inc. | $68.14 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $969.09 | 73 | ABBVIE INC. ($230.56) |
| 2023 | $618.24 | 60 | ABBVIE INC. ($273.73) |
| 2022 | $31.58 | 2 | Teva Pharmaceuticals USA, Inc. ($18.00) |
| 2021 | $19.45 | 2 | Teva Pharmaceuticals USA, Inc. ($15.61) |
All Payment Transactions
137 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.16 | General |
| Category: NEUROSCIENCE | ||||||
| 12/17/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $28.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/10/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $13.75 | General |
| 12/04/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $17.24 | General |
| Category: Obesity | ||||||
| 11/25/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $2.40 | General |
| Category: NEUROSCIENCE | ||||||
| 11/22/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $22.71 | General |
| Category: PSYCHIATRY | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $15.84 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $5.53 | General |
| Category: NEUROSCIENCE | ||||||
| 11/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $1.62 | General |
| Category: NEUROSCIENCE | ||||||
| 10/29/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: NEUROSCIENCE | ||||||
| 10/25/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $13.49 | General |
| Category: Psychology/Psychiatric | ||||||
| 10/22/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $18.29 | General |
| Category: Oncology | ||||||
| 10/21/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $24.16 | General |
| Category: Endocrinology | ||||||
| 10/19/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $23.79 | General |
| Category: RESPIRATORY | ||||||
| 10/15/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $1.32 | General |
| Category: NEUROSCIENCE | ||||||
| 10/09/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $14.41 | General |
| Category: Respiratory | ||||||
| 10/01/2024 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $13.98 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 09/25/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $1.24 | General |
| Category: NEUROSCIENCE | ||||||
| 09/17/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: Obesity | ||||||
| 08/28/2024 | Medtronic, Inc. | INTELLIS ADAPTIVESTIM (Device) | Food and Beverage | In-kind items and services | $27.70 | General |
| Category: Spinal Cord Neurostimulation | ||||||
| 08/20/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.48 | General |
| Category: NEUROSCIENCE | ||||||
| 08/19/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $33.09 | General |
| Category: NEUROSCIENCE | ||||||
| 07/30/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.86 | General |
| Category: NEUROSCIENCE | ||||||
| 07/26/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $22.02 | General |
| Category: NEUROSCIENCE | ||||||
| 07/25/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $2.93 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 9 | 877 | 1,012 | $114,282 | $54,349 |
| 2021 | 12 | 1,181 | 1,305 | $128,654 | $64,459 |
| 2020 | 7 | 490 | 504 | $52,847 | $35,336 |
Total Patients
2,548
Total Services
2,821
Medicare Billing
$154,144
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 220 | 266 | $55,260 | $21,151 | 38.3% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2022 | 246 | 295 | $19,175 | $15,000 | 78.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 150 | 161 | $13,983 | $7,091 | 50.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 111 | 128 | $18,553 | $7,035 | 37.9% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2022 | 31 | 32 | $2,080 | $1,625 | 78.1% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 34 | 35 | $1,925 | $1,232 | 64.0% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 46 | 49 | $2,156 | $889.14 | 41.2% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 11 | 13 | $325.00 | $213.12 | 65.6% |
| 81002 | Urinalysis, manual test | Office | 2022 | 28 | 33 | $825.00 | $113.86 | 13.8% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2021 | 374 | 426 | $27,690 | $21,858 | 78.9% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 125 | 126 | $26,082 | $10,163 | 39.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 128 | 154 | $23,116 | $9,746 | 42.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 58 | 68 | $14,510 | $6,004 | 41.4% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Office | 2021 | 77 | 77 | $11,538 | $4,504 | 39.0% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 205 | 226 | $9,955 | $3,991 | 40.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 38 | 38 | $6,140 | $3,252 | 53.0% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2021 | 35 | 37 | $2,405 | $1,898 | 78.9% |
| 87426 | Elisa detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2021 | 41 | 41 | $2,255 | $1,449 | 64.2% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 23 | 23 | $3,198 | $1,008 | 31.5% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 46 | 53 | $865.00 | $461.04 | 53.3% |
| 81002 | Urinalysis, manual test | Office | 2021 | 31 | 36 | $900.00 | $125.28 | 13.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 113 | 113 | $18,080 | $14,689 | 81.2% |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | Office | 2020 | 188 | 199 | $12,935 | $10,211 | 78.9% |
| 99202 | New patient office or other outpatient visit, typically 20 minutes | Office | 2020 | 69 | 69 | $10,346 | $4,252 | 41.1% |
| 87635 | Sars-cov-2 covid-19 amp prb | Office | 2020 | 74 | 76 | $4,940 | $3,900 | 78.9% |
About Daniel Dean, FNP-BC
Daniel Dean, FNP-BC is a Family healthcare provider based in Jasper, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/09/2020. The National Provider Identifier (NPI) number assigned to this provider is 1689292203.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Daniel Dean, FNP-BC has received a total of $1,638 in payments from pharmaceutical and medical device companies, with $969.09 received in 2024. These payments were reported across 137 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($1,625).
As a Medicare-enrolled provider, Dean has provided services to 2,548 Medicare beneficiaries, totaling 2,821 services with total Medicare billing of $154,144. Data is available for 3 years (2020–2022), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Family
- Location Jasper, GA
- Active Since 07/09/2020
- Last Updated 02/09/2023
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1689292203
Products in Payments
- VRAYLAR (Drug) $391.23
- QULIPTA (Drug) $92.11
- JARDIANCE (Drug) $86.86
- Cologuard Collection Kit (Device) $86.16
- Auvelity (Drug) $82.13
- REXULTI (Drug) $72.68
- TRINTELLIX (Drug) $70.28
- PAXLOVID (Drug) $62.07
- TRELEGY ELLIPTA (Drug) $56.00
- MOUNJARO (Drug) $54.53
- Dexcom G6 Transmitter (Medical Supply) $51.03
- INTELLIS ADAPTIVESTIM (Device) $50.62
- Wegovy (Drug) $41.24
- AREXVY (Drug) $39.56
- BREZTRI (Drug) $28.94
- CAPLYTA (Drug) $28.00
- NEXLETOL (Drug) $21.47
- UBRELVY (Drug) $20.95
- SHINGRIX (Biological) $20.90
- Ozempic (Drug) $19.80
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Jasper
Emily Cummins, Np-C, NP-C
Family — Payments: $23,515
Family $23,515
Caroline Garrett, Np-C, NP-C
Family — Payments: $6,332
Family $6,332
Christina Breitweiser, Fnp-C, FNP-C
Family — Payments: $5,324
Family $5,324
Paula Mccarter-Carlisle, Fnp-C, FNP-C
Family — Payments: $4,972
Family $4,972
Mary Hochkins
Family — Payments: $4,197
Family $4,197
Lottie Davenport, Fnp-C, FNP-C
Family — Payments: $4,154
Family $4,154